- |||||||||| metoclopramide / Generic mfg.
Journal: Prolonged extrapyramidal syndrome due to metoclopramide overdose: a rare case report. (Pubmed Central) - Feb 24, 2025
The findings support that IV biperiden is likely a more reliable pharmacological challenge than oral biperiden for application in proof-of-mechanism studies with novel selective M1-AChR agonists. With the diagnosis of the extrapyramidal syndrome and intramuscular administration of biperiden 5
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Clinical profile of early-onset Parkinson's disease (Poster Hall (Exhibit Hall A)) - Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_701;
In this series, all patients developed classic motor features and showed levodopa response. A third of the patients developed motor fluctuations and dyskinesias.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Journal: Dopamine and acetylcholine have distinct roles in delay- and effort-based decision-making in humans. (Pubmed Central) - Jul 26, 2024
In contrast, delay discounting was reduced under haloperidol, but not affected by biperiden. Together, our data suggest that dopamine, acting at D2 receptors, modulates both effort and delay discounting, while acetylcholine, acting at M1 receptors, appears to exert a more specific influence on effort discounting only.
- |||||||||| Akineton (biperiden) / Endo, AbbVie, NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: OptiSeDent: Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability (clinicaltrials.gov) - Jul 15, 2024
P4, N=40, Active, not recruiting,
Together, our data suggest that dopamine, acting at D2 receptors, modulates both effort and delay discounting, while acetylcholine, acting at M1 receptors, appears to exert a more specific influence on effort discounting only. Unknown status --> Active, not recruiting | Trial completion date: Aug 2014 --> Jul 2025 | Trial primary completion date: Aug 2014 --> Jul 2025
- |||||||||| levofloxacin / Generic mfg.
Journal: Levofloxacin-Induced Oromandibular Dystonia in a 9-Year-Old Patient. (Pubmed Central) - Jul 11, 2024
Unknown status --> Active, not recruiting | Trial completion date: Aug 2014 --> Jul 2025 | Trial primary completion date: Aug 2014 --> Jul 2025 One week before these presentations, he had been prescribed Tavanex
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Clinical, Journal: Cholinergic modulation of motor sequence learning. (Pubmed Central) - May 8, 2024
The beta synchronization after biperiden fits with a disruption of the selective visuospatial attention enhancement associated with initial sequence learning. These findings highlight the role of cholinergic processes in motor sequence learning.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Clinical, Retrospective data, Review, Journal: Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Mar 7, 2024
Cyproheptadine, clonazepam, zolmitriptan, and valproate did not yield significant effects...Trazodone, mianserin, and propranolol appeared as effective alternatives with slightly less favorable efficacy and tolerance profiles. These findings should assist prescribers in selecting an appropriate medication for treating AIA.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Tamsulosin impairs object recognition without affecting anxiety-related behaviors in mice (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_10001;
Biperiden (BPD; 2-4 mg/kg, ip) was used as an amnesic standard...Diazepam (DZP; 1 mg/kg, ip) was used as an anxiolytic standard...2022). Altogether, behavioral effects of tamsulosin contribute to understand its potential side effects, and it can also add to the role played by ?1-adrenoceptor in the etiology of psychopathologies.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Acute laryngeal stridor in the emergency department: pandemic or additional sign? () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_676;
This case reinforces the importance of multidisciplinary collaboration for adequate symptoms approach, by establishing the link between previous medical history and acute respiratory symptoms, particularly in pandemic time. Therefore, the prompted recognition of breathing disorders could be a window of opportunity for disease-modifying interventions.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Hypoxic brain injury: a rare cause of chorea and dystonia () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_301;
Therefore, the prompted recognition of breathing disorders could be a window of opportunity for disease-modifying interventions. With this case report we aim to emphasize that despite rare, chorea can be the main manifestation of an hypoxic brain injury and its recognition is of uttermost importance, avoiding misdiagnosis with the more frequent status epilepticus in the post-anoxic patient, and prompting the beginning of appropriate treatment for controlling this hypekinetic disorder, as well as an adequate rehabilitation program.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Enrollment open: Biperiden Trial for Epilepsy Prevention (clinicaltrials.gov) - Jul 27, 2023
P3, N=312, Recruiting,
With this case report we aim to emphasize that despite rare, chorea can be the main manifestation of an hypoxic brain injury and its recognition is of uttermost importance, avoiding misdiagnosis with the more frequent status epilepticus in the post-anoxic patient, and prompting the beginning of appropriate treatment for controlling this hypekinetic disorder, as well as an adequate rehabilitation program. Not yet recruiting --> Recruiting
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Retrospective data, Review, Journal: Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis. (Pubmed Central) - Jun 1, 2023
There was a high RoB in our included study, especially in terms of dealing with possible cofounders. The limitations of this study suggest a need for more well-designed studies with a longer duration of follow-up on this topic to reach more reliable evidence.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Trial completion date, Trial termination, Trial primary completion date: Use of Biperiden for the Prevention of Post-traumatic Epilepsy (clinicaltrials.gov) - Jan 31, 2023
P3, N=123, Terminated,
In addition, the developed method was used for the therapeutic drug monitoring of biperiden in real patient plasma. Trial completion date: Jul 2021 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Jul 2021 --> Dec 2022; Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Retrospective data, Journal: Time until modification of antiparkinsonian therapy in a group of patients from Colombia. (Pubmed Central) - Dec 23, 2022
After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Preclinical, Journal: Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines. (Pubmed Central) - Nov 30, 2022
Results showed that levetiracetam, valproic acid, and haloperidol were able to induce a relevant synergistic antitumor effect when associated with the chemotherapy currently used in clinic (temozolomide)...Fingolimod appeared to have anoikis-related cell death. Thus, the assayed drugs which are able to cross the blood-brain barrier could represent a possibility to improve the treatment of neural tumors, though future in vivo studies and clinical trials will be necessary to validate it.
- |||||||||| Clinical, Review, Journal: Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. (Pubmed Central) - Nov 25, 2022
There is a direct association between craving and cocaine use, underscoring craving as an important treatment target for promoting abstinence among persons with cocaine use disorder. Clonidine, fenfluramine and m-CPP showed to be promising medications for cocaine craving in the short-term treatment, and amphetamine, biperiden, carbamazepine, lisdexamfetamine, lorcaserin, methamphetamine, mirtazapine, pioglitazone, progesterone, guanfacine, levodopa, nefazodone in the long-term treatment.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Journal: Novel Chromone-Containing Allylmorpholines Induce Anxiolytic-like and Sedative Effects in Adult Zebrafish. (Pubmed Central) - Nov 16, 2022
To assess the potential contribution of the glutamate and cholinergic mechanisms in the effects of the CCAMs, we conducted experiments with pre-exposure to putative antagonists, NMDA and biperiden...The apparent discrepancy could be related to the specifics of CCAM metabolism or to the interspecies differences between the putative target proteins, possibly due to the relatively low identity percentage of their sequences. Although further research in mammals is required in order to establish their pharmacological properties, novel CCAMs may represent an appealing group of psychoactive drug candidates.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Withdrawal Dyskinesia: A Case Report and a Systematic Review of the Literature () - Oct 19, 2022 - Abstract #AACAP2022AACAP_1041;
When treating patients on antipsychotics or assessing patients with involuntary movements, WD is an important phenomenon for which to monitor. More research is needed to evaluate treatment options and their successes, although clonidine may be considered as a treatment option based on the results of our case.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Time to Modification of Antiparkinson Therapy in a Group of patients from Colombia () - Jun 24, 2022 - Abstract #MDSPAS2022MDS_PAS_46;
After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications of the therapy, with a mean time of three years. Male sex, age over 65 years and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Journal: Cholinergic models of memory impairment in animals and man: scopolamine vs. biperiden. (Pubmed Central) - Jun 4, 2022
It is concluded that the effects on cognitive functions are different for scopolamine and biperiden, and they should be considered as different cognitive deficit models. Scopolamine may model more advanced stages of Alzheimer's disease whereas biperiden may model the early deficits in declarative memory in aging and mild cognitive impairment.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Review, Journal: Misuse of Anticholinergic Medications: A Systematic Review. (Pubmed Central) - Feb 26, 2022
(4) Results from the present study show that anticholinergic misusing issues are both widespread worldwide and popular. Considering the potential adverse effects associated, healthcare professionals should be vigilant and monitor eventual misusing issues.
- |||||||||| Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, Journal: Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study. (Pubmed Central) - Feb 25, 2022
In cohort 1 (n = 97), patients received 40-80 mg/day blonanserin transdermal patches for one year after taking 8-16 mg/day blonanserin tablets for 6 weeks, and the dose of patches was determined based on the dose of the tablets...Changes from the start of transdermal patch treatment in EPS and the dose of antiparkinsonian drugs at 3, 6, and 12 months were assessed using the Drug-Induced EPS Scale (DIEPSS) and biperiden equivalents of total antiparkinsonian drugs (BPD-eq), respectively...In contrast, there were no significant changes from the start of patch treatment in BPD-eq at any month (p > 0.05). Transdermal patches of blonanserin are a more effective route of administration to diminish EPS than oral tablets/powder.
- |||||||||| ketamine / Generic mfg.
Journal: Bicaudal-C protein, a potential antidepressant target. (Pubmed Central) - Feb 8, 2022
Clarifying the relationship between Bicaudal-C protein and depression may help us to find new antidepressants. This review focuses on the research advances of the relationship between Bicaudal-C protein and depression.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal, Real-world evidence: Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. (Pubmed Central) - Dec 25, 2021
We evaluated the use of LAIs antipsychotics [aripiprazole-1-month (A1M); paliperidone-1-month and 3-month (PP1M and PP3M) and biweekly (2w)-LAIs] and their corresponding oral formulations through (1) the number of hospital re-admissions, (2) the number of documented suicidal behaviour/attempts and (3) the use of concomitant benzodiazepines, oral antipsychotics and biperiden...Our results showed that LAIs associated significantly lower suicidal behaviour, reduced the number of hospital admissions, lower diazepam and haloperidol equivalents and mean daily dose of biperiden intake versus oral antipsychotics...In conclusion, LAIs improved clinical outcomes by reducing the need for concomitant treatments and hospital admissions over oral antipsychotics. PP1M and PP3M showed better outcomes versus A1M and biweekly LAIs.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal, Real-world evidence: Off-label use of second-generation antipsychotics in borderline personality disorder: a comparative real-world study among oral and long-acting injectables in Spain. (Pubmed Central) - Dec 25, 2021
The aim of the present study was to evaluate the use of oral vs. long-acting injectables (LAIs) antipsychotics, as well as, to compare the effectiveness of different LAI antipsychotics [aripiprazole-1-month, paliperidone-1-month (PP1M), paliperidone-3-month (PP3M) and risperidone long-acting injectable (RLAI)] in patients diagnosed with borderline personality disorder (BPD), by evaluating the following clinical outcomes: (1) the number of hospital admissions; (2) the number of documented suicidal behaviour/attempts; and (3) the use of concomitant treatments, including benzodiazepines, oral antipsychotics and biperiden...Moreover, PP1M and PP3M used lower daily dose of diazepam equivalents compared with the aripiprazole-1-month and RLAI treatment groups. In conclusion, the use of LAIs may play a role in the management of BPD.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Metoclopramide induced acute dystonic reaction during labor ([VIRTUAL]) - Oct 31, 2021 - Abstract #Euroanaesthesia2021Euroanaesthesia_643;
Following multidisciplinary discussion including Neurology, Diazepam 5mg and Biperiden 5mg were administered, with a reduction of dystonic movements amplitude...Management of acute dystonic reactions involve discontinuation of metoclopramide and early administration of anticholinergic drugs. Good communication is essential, especially in emergency scenarios.
- |||||||||| Akineton (biperiden) / Endo, AbbVie, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Biomarker, Review, Journal: Selected Molecular Targets for Antiepileptogenesis. (Pubmed Central) - Oct 30, 2021
Among the approved non-antiepileptic drugs, antiepileptogenic potential seems to reside in losartan (a blocker of angiotensin II type 1 receptors), biperiden (an antiparkinsonian drug), nonsteroidal anti-inflammatory drugs, antioxidative drugs and minocycline (a second-generation tetracycline with anti-inflammatory and antioxidant properties)...Exceptionally, in this regard, our own original data presented here point to c-Fos as an early seizure duration, but not seizure intensity-related, marker of early epileptogenesis. Further research of reliable markers of early epileptogenesis is definitely needed to improve the process of designing adequate antiepileptogenic therapies.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Trial completion date, Trial initiation date, Trial primary completion date: Biperiden Trial for Epilepsy Prevention (clinicaltrials.gov) - Oct 21, 2021
P3, N=312, Not yet recruiting,
Further research of reliable markers of early epileptogenesis is definitely needed to improve the process of designing adequate antiepileptogenic therapies. Trial completion date: Dec 2025 --> Dec 2026 | Initiation date: Sep 2021 --> Feb 2022 | Trial primary completion date: Dec 2025 --> Dec 2026
- |||||||||| Silenor (doxepin) / Currax
Clinical, Journal: Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients. (Pubmed Central) - Oct 20, 2021
Most prescribed drugs were promethazine (n = 2996), olanzapine (n = 2561), biperiden (n = 1074), and doxepin (n = 963)...Anticholinergic ADRs can be prevented by avoiding high-risk drug combinations. Replacing tricyclic antidepressants and first-generation antihistamines with drugs with lower anticholinergic potential and avoiding biperiden could reduce 59.3% of anticholinergic drug application.
- |||||||||| amantadine / Generic mfg.
[VIRTUAL] Hypersexual disorder in GBA-associated Parkinson's Disease: Case report () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_1042;
He started using pramipexole, being after changed by levodopa, amantadine, and biperiden at the age of 41, which were used until evaluation. Even being at high risk for impulsive control disorders (male, early-onset disease with high levodopa dose), GBA variants may have a role in compulsive sexual behavior.
- |||||||||| ondansetron / Generic mfg., metoclopramide / Generic mfg.
Journal: A toddler with status dystonicus due to medication (Pubmed Central) - Aug 25, 2021
Metoclopramide holds a relatively high risk for extrapyramidal complications (1-10%) and dystonia (0.1-1.5%), even within therapeutic range. The use of anti-emetics with less alarming side effect profiles, for example ondansetron, is recommended.
|
